Clinical Trial Update: The Efficacy and Safety of TACE, Lenvatinib and Camrelizumab in the Treatment of BCLC Stage B/C Hepatocellular Carcinoma: a Single-arm, Single-center, Open-label Study [Phase 2, Phase 3]

View source ↗

Summary

A single-arm study evaluating the combination of transarterial chemoembolization (TACE), lenvatinib, and camrelizumab for BCLC stage B/C hepatocellular carcinom…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Camrelizumab (camrelizumab)
• Lenvatinib (lenvatinib)
• TACE

Snippet

Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Conditions: Hepatocellular Carcinoma | Phase 2, Phase 3 | Status: UNKNOWN